Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 2,501–2,600 of 10,906
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design
Pfeifer, B. A., Beitelshees, M., Hill, A. B., Bassett, J., & Jones, C. H. (2023) · npj Systems Biology and Applications · doi:10.1038/s41540-023-00323-3 · Cited by 42
Heterogeneity in Spatial Inequities in COVID-19 Vaccination Across 16 Large US Cities
Bilal, U., Mullachery, P. H., Schnake-Mahl, A. S., Rollins, H., McCulley, E. M., Kolker, J., Barber, S., & Roux, A. V. D. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac076 · Cited by 30
Yeasts as a promising delivery platform for DNA and RNA vaccines
Silva, A. J. D., de Macêdo, L. S., Leal, L. R. S., de Jesus, A. L. S., & de Freitas, A. C. (2021) · FEMS Yeast Research · doi:10.1093/femsyr/foab018 · Cited by 36
Kumar, M., Kumari, N., Thakur, N., Bhatia, S. K., Saratale, G. D., Ghodake, G. S., Mistry, B. M., Alavilli, H., Kishor, D. S., Du, X., et al. (2021) · Plants · doi:10.3390/plants10061213 · Cited by 35
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · medRxiv · doi:10.1101/2021.03.31.21254660 · Cited by 30
SARS -CoV-2 T-cell immunity to variants of concern following vaccination
Gallagher, K. M. E., Leick, M. B., Larson, R. C., Berger, T. R., Katsis, K., Yam, J. Y., Brini, G., Grauwet, K., MGH COVID-19 Collection & Processing Team, & Maus, M. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.03.442455 · Cited by 31
Hazlewood, G. S., Pardo, J. P., Barnabe, C. C. M., Schieir, O., Barber, C. E. H., Bernatsky, S., Colmegna, I., Hitchon, C. A., Loeb, M. B., Mertz, D., et al. (2021) · The Journal of Rheumatology · doi:10.3899/jrheum.210288 · Cited by 35
Valentin, A., Bergamaschi, C., Rosati, M., Angel, M., Burns, R., Agarwal, M., Gergen, J., Petsch, B., Oostvogels, L., Loeliger, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945706 · Cited by 34
Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data
Hulme, W. J., Williamson, E., Horne, E. M. F., Green, A. C. A., McDonald, H. I., Walker, A. J., Curtis, H. J., Morton, C. E., MacKenna, B., Croker, R., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m21-4269 · Cited by 45
Woldemeskel, B. A., Dykema, A. G., Garliss, C. C., Cherfils, S., Smith, K. N., & Blankson, J. N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156083 · Cited by 31
Walker, J. L., Schultze, A., Tazare, J., Tamborska, A., Singh, B., Donegan, K., Stowe, J., Morton, C. E., Hulme, W. J., Curtis, H. J., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.010 · Cited by 30
Lee, D. S., Kim, J. W., Lee, K. L., Jung, Y. J., & Kang, H. W. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.007 · Cited by 32
Lázaro-Frías, A., Pérez, P., Zamora, C., Sánchez‐Cordón, P. J., Guzmán, M. G., Luczkowiak, J., Delgado, R. B., Casasnovas, J. M., Estéban, M., & García‐Arriaza, J. (2022) · npj Vaccines · doi:10.1038/s41541-022-00440-w · Cited by 32
Nanoparticles and Antiviral Vaccines
Liu, S., Hu, M., Liu, X., Liu, X., Chen, T., Zhu, Y., Liang, T., Xiao, S., Li, P., & Ma, X. (2023) · Vaccines · doi:10.3390/vaccines12010030 · Cited by 40
Cationic Lipid Pairs Enhance Liver-to-Lung Tropism of Lipid Nanoparticles for In Vivo mRNA Delivery
Zeng, G., He, Z., Yang, H., Gao, Z., Ge, X., Liu, L., Liu, Z., & Chen, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c02415 · Cited by 33
SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans
Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.728021 · Cited by 30
Coronavirus Disease 2019: Clinics, Treatment, and Prevention
Burkert, F. R., Lanser, L., Bellmann‐Weiler, R., & Weiß, G. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.761887 · Cited by 36
Myocarditis following COVID-19 vaccination: incidence, mechanisms, and clinical considerations
Power, J. R., Keyt, L. K., & ADLER, E. D. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2066522 · Cited by 37
Stark, F. C., Akache, B., Deschatelets, L., Tran, A., Stuible, M., Durocher, Y., McCluskie, M. J., Agbayani, G., Dudani, R., Harrison, B. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13819-5 · Cited by 33
Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-021-02183-3 · Cited by 34
A Versatile Strategy to Transform Cationic Polymers for Efficient and Organ‐Selective mRNA Delivery
Lin, L., Su, K., Zhang, X., Shi, L., Yan, X., Fu, Q., Yao, K., Siegwart, D. J., & Liu, S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202500306 · Cited by 34
Hall, V. G., Al-Alahmadi, G., Solera, J. T., Marinelli, T. M., Cardinal, H., Prasad, G. V. R., Serres, S. A. D., Isaac, D., Mainra, R., Lamarche, C., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004178 · Cited by 32
Targeting the hallmarks of aging to improve influenza vaccine responses in older adults
Cadar, A. N., Martin, D. E., & Bartley, J. M. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00348-6 · Cited by 36
Boulouis, C., Kammann, T., Cuapio, A., Parrot, T., Gao, Y., Mouchtaridi, E., Wullimann, D., Lange, J., Chen, P., Akber, M., et al. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00484-7 · Cited by 29
Binici, B., Borah, A., Watts, J. A., McLoughlin, D. M., & Perrie, Y. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124942 · Cited by 34
COVID-19 and liver injury: An ongoing challenge
Papagiouvanni, I., Kotoulas, S., Pataka, A., Spyratos, D. G., Porpodis, Κ., Boutou, A., Papagiouvannis, G., Grigoriou, I., Vettas, C., & Goulis, I. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.257 · Cited by 33
Asano, M., Okada, H., Itoh, Y., Hirata, H., Ishikawa, K., Yoshida, E., Matsui, A., Kelly, E. J., Shoemaker, K., Olsson, U., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.030 · Cited by 34
Pérez, P., Lázaro-Frías, A., Zamora, C., Sánchez‐Cordón, P. J., Astorgano, D., Luczkowiak, J., Delgado, R. B., Casasnovas, J. M., Estéban, M., & García‐Arriaza, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.824728 · Cited by 31
Familial thrombocytopenia flare‐up following the first dose of mRNA ‐1273 Covid ‐19 vaccine
Toom, S., Wolf, B., Avula, A., Peeke, S. Z., & Becker, K. D. (2021) · American Journal of Hematology · doi:10.1002/ajh.26128 · Cited by 30
Fernández-Ruiz, M., Almendro-Vázquez, P., Carretero, O., Ruiz-Merlo, T., Laguna-Goya, R., Juan, R. S., López‐Medrano, F., García‐Ríos, E., Más, V., Moreno-Batenero, M., et al. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001246 · Cited by 33
Domi, M., Leitson, M., Gifford, D. R., Nicolaou, A., Sreenivas, K., & Bishnoi, C. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17224 · Cited by 29
All organic nanomedicine for PDT–PTT combination therapy of cancer cells in hypoxia
Urazaliyeva, A., Kanabekova, P., Beisenbayev, A. R., Kulsharova, G., Atabaev, T. S., Kim, S., & Lim, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-68077-4 · Cited by 36
Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies
Wang, J., Wang, Q., Ma, L., Lv, K., Han, L., Chen, Y., Zhou, R., Zhou, H., Chen, H., Wang, Y. H., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.036 · Cited by 36
Self-citationGarrett, M. E., Galloway, J. G., Wolf, C., Logue, J. K., Franko, N., Chu, H. Y., Matsen, F. A., IV, & Overbaugh, J. (2022) · eLife · doi:10.7554/elife.73490 · Cited by 38
Tuan, J., Zapata, H. J., Critch‐Gilfillan, T., Ryall, L., Turcotte, B., Mutic, S., Andrews, L., Roh, M. E., Friedland, G., Barakat, L., et al. (2021) · HIV Medicine · doi:10.1111/hiv.13188 · Cited by 30
Gueguen, J., Colosio, C., Bello, A. D., Scemla, A., N’Guyen, Y., Rouzaud, C., Carvalho-Schneider, C., Gautier-Vargas, G., Tremolières, P., Eddine, A. J., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.03.020 · Cited by 38
Thrombotic events and COVID-19 vaccines
Brazete, C. S., Aguiar, A., Furtado, I., & Duarte, R. (2021) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0298 · Cited by 35
Porru, S., Monaco, M. G. L., Spiteri, G., Carta, A., Pezzani, M. D., Lippi, G., Gibellini, D., Tacconelli, E., Vecchia, I. D., Sala, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081193 · Cited by 36
Hirani, R., Noruzi, K. A., Iqbal, A., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11112713 · Cited by 30
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 43
“Following the approval of the first LNP-siRNA drug (Adams et al. 2018; Akinc et al. 2019) and the COVID-19 LNP-mRNA vaccines (Baden et al. 2021; Polack et al. 2020), LNP-mRNA platform technology is currently being applied for various immunotherapy approaches, including treatment of infectious…”
Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
Hijikata, A., Shionyu‐Mitsuyama, C., Nakae, S., Shionyu, M., Ota, M., Kanaya, S., Hirokawa, T., Nakajima, S., Watashi, K., & Shirai, T. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13337 · Cited by 30
Hoek, R. A. S., Verschuuren, E. A. M., de Vries, R. D., Vonk, J. M., van Baarle, D., van der Heiden, M., van Gemert, J. P., Gore, E. J., Niesters, H. G. M., Erasmus, M. E., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.03.006 · Cited by 31
Kirkham, A. M., Bailey, A. J.-M., Monaghan, M., Shorr, R., Lalu, M. M., Fergusson, D. A., & Allan, D. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac038 · Cited by 35
Day, D., Grech, L., Nguyen, M., Bain, N. T., Kwok, A., Harris, S., Chau, H., Chan, B. A., Blennerhassett, R. C., Nott, L. M., et al. (2022) · Vaccines · doi:10.3390/vaccines10060851 · Cited by 30
Shurtleff, V. W., Layton, M. E., Parish, C. A., Perkins, J. J., Schreier, J. D., Wang, Y., Adam, G. C., Álvarez, N., Bahmanjah, S., Bahnck-Teets, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02248 · Cited by 33
High Recovery Chromatographic Purification of mRNA at Room Temperature and Neutral pH
Miklavčič, R., Megušar, P., Kodermac, Š. M., Bakalar, B., Dolenc, D., Sekirnik, R., Štrancar, A., & Černigoj, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814267 · Cited by 35
Structure and antigenicity of divergent Henipavirus fusion glycoproteins
Isaacs, A., Low, Y. S., Macauslane, K. L., Seitanidou, J., Pegg, C. L., Cheung, S. T. M., Liang, B., Scott, C. A. P., Landsberg, M. J., Schulz, B. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39278-8 · Cited by 31
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
Nappi, E., Santis, M. D., Paoletti, G., Pelaia, C., Terenghi, F., Pini, D., Ciccarelli, M., Selmi, C. F., Puggioni, F., Canonica, G. W., et al. (2022) · Vaccines · doi:10.3390/vaccines10050716 · Cited by 30
Opportunities for innovation: Building on the success of lipid nanoparticle vaccines
Huang, J. Y., Yuen, D., Mintern, J. D., & Johnston, A. P. R. (2021) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2021.101468 · Cited by 36
Grunau, B. E., Asamoah-Boaheng, M., Lavoie, P. M., Karim, M. E., Kirkham, T. L., Demers, P. A., Barakauskas, V., Marquez, A. C., Jassem, A. N., O’Brien, S. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab938 · Cited by 35
SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges
Wellens, J., Colombel, J., Satsangi, J. J., & Wong, S.-Y. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab046 · Cited by 32
Elberry, M. H., Ahmed, H., Hamdallah, A., Abdella, W. S., Sayed, A., Ghaith, H. S., & Negida, A. (2022) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02626-w · Cited by 32
Dumont, R., Richard, V., Lorthe, E., Loizeau, A., Pennacchio, F., Zaballa, M.-E., Baysson, H., Nehme, M., Perrin, A., L’Huillier, A. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34616-8 · Cited by 41
Meunier, L., Sanavio, M., Dumortier, J., Meszaros, M., Faure, S., Bedoya, J. U., Echenne, M., Boillot, O., Debourdeau, A., & Pageaux, G. (2022) · Liver International · doi:10.1111/liv.15258 · Cited by 35
Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 30
Caiazzo, V., & Stimpfel, A. W. (2022) · Public Health · doi:10.1016/j.puhe.2022.03.017 · Cited by 32
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
Laurini, G. S., Montanaro, N., Broccoli, M., Bonaldo, G., & Motola, D. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.054 · Cited by 32
Pratama, N. R., Wafa, I. A., Budi, D. S., Sutanto, H., Asmarawati, T. P., Barlian Effendi, G., & Wungu, C. D. K. (2022) · Vaccines · doi:10.3390/vaccines10122180 · Cited by 30
“, 2021(24) Casecontrol South Africa 52,468 > 18 Omicron period N/A 0-13 days group 8 (5-11) days 14-27 days group 20 (17-24) days 1-2 months group 32 (29-34) days Ad26.”
Return on Investment of the COVID-19 Vaccination Campaign in New York City
Sah, P., VILCHES, T. N., Moghadas, S. M., Pandey, A., Gondi, S., Schneider, E. C., Singer, J., Chokshi, D. A., & Galvani, A. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.43127 · Cited by 30
Taus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 34
Yamamoto, S., Fukunaga, A., Tanaka, A., Takeuchi, J. S., Inoue, Y., Kimura, M., Maeda, K., Ueda, G., Mizoue, T., Ujiie, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.02.052 · Cited by 30
Interspecies Jumping of Bat Coronaviruses
Wong, A. C. P., Lau, S. K. P., & Woo, P. C. Y. (2021) · Viruses · doi:10.3390/v13112188 · Cited by 36
Zhao, Y., Du, J., Li, Z., Xu, Z., Wu, Y., Duan, W., Wang, W., Zhang, T., Xu, J., Wu, H., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28509 · Cited by 33
Grupper, A., Katchman, E. A., Ben‐Yehoyada, M., Rabinowich, L., Schwartz, D., Schwartz, I. F., Shashar, M., Halperin, T., Turner, D., Goykhman, Y., et al. (2021) · Clinical Transplantation · doi:10.1111/ctr.14478 · Cited by 29
COVID‐19: Clinical status of vaccine development to date
Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. K. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 36
Design of Experiments to Achieve an Efficient Chitosan-Based DNA Vaccine Delivery System
Rodolfo, C., Eusébio, D., Ventura, C., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091369 · Cited by 30
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Gordon, J. E., Speicher, L. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.12.002 · Cited by 34
de Boer, S. E., Berger, S. P., van Leer‐Buter, C., Kroesen, B., van Baarle, D., Sanders, J., & on behalf of the OPTIMIZE study group (2022) · Transplantation · doi:10.1097/tp.0000000000004177 · Cited by 31
Gepner, Y., Mofaz, M., Oved, S., Yechezkel, M., Constantini, K., Goldstein, N., Eisenkraft, A., Shmueli, E., & Yamin, D. (2022) · Communications Medicine · doi:10.1038/s43856-022-00090-y · Cited by 28
Inhalable Dry Powders for Lung mRNA Delivery
Gordon, A. G. R., Li, B., Witten, J. J., Nguyen, H. Q., & Anderson, D. G. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400509 · Cited by 38
Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Zhu, Q., Xu, Y., Wang, T., & Xie, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053437 · Cited by 34
Murray, M. J., McIntosh, M., Atkinson, C. E., Mahungu, T. W., Wright, E., Chatterton, W., Gandy, M., & Reeves, M. B. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.010 · Cited by 33
CRISPR-Cas13b-mediated suppression of HBV replication and protein expression
McCoullough, L. C., Fareh, M., Hu, W., Sozzi, V., Makhlouf, C., Droungas, Y., Lee, C. L., Takawy, M., Fabb, S. A., Payne, T. J., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.025 · Cited by 31
COVID-19 vaccines: progress and understanding on quality control and evaluation
Mao, Q., Xu, M., He, Q., Li, C., Meng, S., Wang, Y., Cui, B., Liang, Z., & Wang, J. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00621-4 · Cited by 31
Patel, D. R., Field, C. J., Septer, K. M., Sim, D. G., Jones, M. J., Heinly, T. A., Vanderford, T. H., McGraw, E. A., & Sutton, T. C. (2021) · Journal of Virology · doi:10.1128/jvi.02232-20 · Cited by 33
Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
Lee, E.-J., & Oh, J. E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0075 · Cited by 30
Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2
Castonguay, N., Zhang, W., & Langlois, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.676314 · Cited by 29
Sa, S., Lee, C. W., Shim, S. R., Yoo, H., Choi, J., Kim, J. H., Lee, K., Hong, M., & Han, H. W. (2022) · Vaccines · doi:10.3390/vaccines10020320 · Cited by 31
Vaccine market and production capabilities in the Americas
Ortiz‐Prado, E., Espín, E., Vásconez-González, J., Rodríguez-Burneo, N., Kyriakidis, N. C., & López‐Cortés, A. (2021) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-021-00135-5 · Cited by 35
Camacho-Moll, M. E., Salinas-Martínez, A. M., Cisneros, B. T., Onofre, J. I. G., Floriano, G. N., & de León, M. B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.834744 · Cited by 31
Xu, C., Wang, A., Geng, K., Honnen, W. J., Wang, X., Bruiners, N., Singh, S., Ferrara, F., D’Angelo, S., Bradbury, A. M., et al. (2021) · Viruses · doi:10.3390/v13060953 · Cited by 30
Yendewa, S. A., Ghazzawi, M., James, P., Smith, M. E., Massaquoi, S. P. E., Babawo, L. S., Deen, G. F., Russell, J. B., Samai, M. H., Sahr, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10050757 · Cited by 28
Räuber, S. J., Korsen, M., Huntemann, N., Rolfes, L., Müntefering, T., Dobelmann, V., Hermann, A. M., Kölsche, T., Lipinski, K. V. W., Schroeter, C. B., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328197 · Cited by 35
Secret messengers: Extracellular RNA communication in the immune system
Nation, G. K., Saffold, C. E., & Pua, H. H. (2021) · Immunological Reviews · doi:10.1111/imr.13027 · Cited by 29
Mehta, S. H., Clipman, S. J., Wesolowski, A., & Solomon, S. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-96779-6 · Cited by 40
Ohno, H., Akamine, S., Mochizuki, M., Hayashi, K., Akichika, S., Suzuki, T., & Saito, H. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad019 · Cited by 34
mRNA vaccines: A novel weapon to control infectious diseases
Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 31
Mooij, P., García‐Arriaza, J., Pérez, P., Lázaro-Frías, A., Verstrepen, B. E., Böszörményi, K. P., Mortier, D., Fagrouch, Z. C., Kiemenyi-Kayere, G., Niphuis, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845887 · Cited by 32
Zhao, Y., Tian, Z., Wang, J., Cui, M., Cao, Z., Liu, P., Li, R., Cai, S., Hu, Y., Ma, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady6460 · Cited by 42
“Their utility was further demonstrated during the COVID-19 pandemic ( 2 , 3 ), enabling the rapid development and global deployment of mRNA vaccines, including Pfizer-BioNTech’s BNT162b2 ( 4 ) and Moderna’s mRNA-1273 ( 5 ).”
Hanly, M., Churches, T., Fitzgerald, O., Caterson, I. D., MacIntyre, C. R., & Jorm, L. R. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08447-8 · Cited by 33
Dong, Z., Huang, Z., Li, S., Wang, Y., Yao, Y., Yang, X., & Xu, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.021 · Cited by 32
Renn, M., Bartok, E., Zillinger, T., Hartmann, G., & Behrendt, R. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107931 · Cited by 30
Martellucci, C. A., Flacco, M. E., Soldato, G., Martino, G. D., Carota, R., Caponetti, A., & Manzoli, L. (2022) · Vaccines · doi:10.3390/vaccines10050662 · Cited by 34
Syversen, S. W., Jyssum, I., Tveter, A. T., Sexton, J., Christensen, I. E., Tran, T. T., Bjørlykke, K. H., Mjaaland, S., Warren, D. J., Kvien, T. K., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002417 · Cited by 30
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Shen, J., Fan, J., Zhao, Y., Jiang, D., Niu, Z., Zhang, Z., & Cao, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1159326 · Cited by 44
Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics
Asada, K., Komatsu, M., Shimoyama, R., Takasawa, K., Shinkai, N., Sakai, A., Bolatkan, A., Yamada, M., Takahashi, S., Machino, H., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090886 · Cited by 32
Retinal Hemorrhage after SARS-CoV-2 Vaccination
Park, H. S., Byun, Y., Byeon, S. H., Kim, S. S., Kim, Y. J., & Lee, C. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235705 · Cited by 30
A Vaccination Strategy for Ontario COVID-19 Hotspots and Essential Workers
Mishra, S., Stall, N. M., Ma, H., Odutayo, A., Kwong, J. C., Allen, U., Brown, K. A., Bogoch, I. I., Erman, A., Huynh, T., et al. (2021) · doi:10.47326/ocsat.2021.02.26.1.0 · Cited by 36
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.